A Randomised, Double-Blinded, Double-Dummy, Placebo-Controlled, MultiCentre-, Six-Way, Crossover Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of Abediterol Single Dose, Given by Dry Powder Inhaler (DPI) or Pressurised Metered-Dose Inhaler (pMDI), in Patients With Asthma on Inhaled Corticosteroids

Trial Profile

A Randomised, Double-Blinded, Double-Dummy, Placebo-Controlled, MultiCentre-, Six-Way, Crossover Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of Abediterol Single Dose, Given by Dry Powder Inhaler (DPI) or Pressurised Metered-Dose Inhaler (pMDI), in Patients With Asthma on Inhaled Corticosteroids

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs Abediterol (Primary) ; Abediterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 22 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.
    • 22 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top